Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).

Author: FraserGraeme L, KrollRobin, LademacherChristopher, LedermanSamuel, RamaelSteven, SantoroNanette, SkillernLaurence, WaldbaumArthur, YoungJames

Paper Details 
Original Abstract of the Article :
OBJECTIVE: In the primary analysis of the phase 2b VESTA study, oral fezolinetant reduced frequency and severity of menopausal vasomotor symptoms (VMS) compared with placebo. This secondary analysis evaluates effects of fezolinetant on responder rates and patient-reported outcomes (PROs). METHODS: ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/32769757

データ提供:米国国立医学図書館(NLM)

Fezolinetant: A Potential Oasis for Menopausal Symptoms

The realm of [menopause research] is a vast desert, often riddled with discomfort for those traversing its landscape. This study, a veritable camel caravan, aims to quench the thirst of women struggling with the [vasomotor symptoms (VMS)] that accompany menopause. It utilizes the [randomized, placebo-controlled, double-blind, dose-ranging study] approach to investigate the efficacy of [oral fezolinetant] in addressing these symptoms.

The researchers set out to explore the [effects of fezolinetant on responder rates and patient-reported outcomes (PROs)]. They discovered that fezolinetant, compared to placebo, led to a significant increase in the proportion of women experiencing a reduction in VMS, as measured by daily diary records.

Fezolinetant: A Beacon of Hope for Menopausal Relief

The results were quite striking. Fezolinetant significantly improved the quality of life for these women, exceeding the minimally important differences (MIDs) for various quality-of-life measures. This means that the improvements observed were clinically meaningful and not just statistically significant.

Navigating the Desert of Menopause with Fezolinetant

With its ability to decrease the frequency and severity of hot flashes and improve overall well-being, fezolinetant offers a potential respite from the [challenges of menopause]. While further research is needed to understand its long-term effects, this study sheds light on the promising potential of this drug to improve the lives of postmenopausal women.

Dr.Camel's Conclusion

This study is like a refreshing oasis in the desert of menopause research. Fezolinetant shows promise for alleviating the discomforts associated with menopause. It's like a soothing balm for the weary traveler in this vast desert of hormonal changes. However, just like a mirage, it's important to be aware of the potential side effects and to consult with a doctor before using any medication.

Date :
  1. Date Completed 2021-04-27
  2. Date Revised 2022-10-05
Further Info :

Pubmed ID

32769757

DOI: Digital Object Identifier

00042192-202012000-00004

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.